Latest Morphinans Stories

AcelRx to Present Top-Line Data from Phase 3 Study of Sufentanil NanoTab® PCA System vs. IV PCA Morphine at the 66th Annual PostGraduate Assembly in Anesthesiology held in New York City

2012-12-14 08:24:31

REDWOOD CITY, Calif., Dec. 14, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that top-line data from its previously announced open-label, active-comparator study of its lead product candidate, the Sufentanil NanoTab PCA System, will be featured in poster presentations to be held at the 66(th)...

Endo Health Solutions Launches 7.5mg and 15mg strengths of Reformulated, Designed to be Crush-Resistant, OPANA® ER

2012-12-11 12:27:59

CHADDS FORD, Pa., Dec. 11, 2012 /PRNewswire/ -- Endo Health Solutions Inc. (Nasdaq: ENDP) announced today that its subsidiary, Endo Pharmaceuticals Inc., has launched 7.5mg and 15mg strengths of its reformulated, designed to be crush-resistant, OPANA(®) ER (oxymorphone HCl) product. Now commercially available, the 7.5mg and 15mg options complete the launch of all approved strengths of the reformulated version of OPANA ER with INTAC(®) technology. The product is now available in...

Naltrexone Helps Ex-Smokers Keep Weight Gain To A Minimum

2012-12-11 11:55:32

Connie K. Ho for redOrbit.com – Your Universe Online You start off by kicking the smoking habit. Then you try to curb the hunger aches you have. For those who have suffered this situation in the past, researchers recently discovered a drug that can help ex-smoking women keep weight gain to a minimum. The study, conducted by the University of Chicago Medical Center, focused on naltrexone and is the first medication in a study that has shown to help women decrease weight gain a...

Qualitest Issues Voluntary, Nationwide Recall of 101 Lots of Hydrocodone Bitartrate and Acetaminophen Tablets, USP 10 mg/500 mg Due to the Potential for Oversized Tablets

2012-12-06 20:22:11

HUNTSVILLE, Ala., Dec. 6, 2012 /PRNewswire/ -- Qualitest, a subsidiary of Endo Health Solutions, (Nasdaq: ENDP) today issued a voluntary nationwide recall for 101 lots of Hydrocodone Bitartrate and Acetaminophen Tablets, USP 10 mg/500 mg. This includes product with the following NDC numbers and lot numbers beginning with the letter "C". NDC Number Bottle Count ---------- ------------ 0603-3888-16 30...

Drug Abuse - Getting Clean for the Holidays and New Year: Connect with Expert Sources on Prescription Drug Abuse Among Professionals, Get Insights on Myths, Treatments and Technology's Role

2012-12-03 16:23:42

WEST BLOOMFIELD, Mich., Dec. 3, 2012 /PRNewswire/ -- WHY NOW: With the holiday season upon us and New Year's resolutions coming soon, people who have become dependent on substances may be more inclined to seek help in overcoming their addiction as they head home to reunite with family and friends, or attempt to start a new life in the new year. However, of those who seek assistance, as many as 70 percent will fail to get clean. Despite the statistics, there is hope - and success -...

Extra Sleep Could Decrease A Person's Sensitivity To Pain

2012-12-02 09:47:04

redOrbit Staff & Wire Reports – Your Universe Online People who find themselves relying on painkillers to ease their discomfort might be better off just trying to catch a few extra hours of sleep, according to a new study published in the December issue of the journal Sleep. According to The Telegraph, research conducted by experts at the Henry Ford Hospital and Wayne State University discovered that getting 10 hours of sleep per night is more effective at reducing pain...

Endo Health Solutions Sues FDA to Protect Consumers from Non-Tamper Resistant Oxymorphone

2012-11-30 16:22:40

CHADDS FORD, Pa., Nov. 30, 2012 /PRNewswire/ -- Endo Health Solutions Inc. (Nasdaq: ENDP) announced today that its subsidiary, Endo Pharmaceuticals Inc., has filed suit against the U.S. Food and Drug Administration (FDA) seeking a formal determination whether the original formulation of OPANA(® )ER (oxymorphone HCl) was voluntarily removed from the market in 2012 for reasons of safety involving the misuse of the drug; and FDA's immediate suspension of any abbreviated new drug...

CLAAD Recognizes SMART/Script as Top 5 Technology To Reduce Rx Abuse

2012-11-27 08:28:29

WASHINGTON, Nov. 27, 2012 /PRNewswire-USNewswire/ -- The Center for Lawful Access and Abuse Deterrence (CLAAD) today honored Atlantic Pharmaceuticals' SMART/Script as one of its "Top 5 Technologies To Reduce Prescription Drug Abuse." Still in investigational stages, the SMART/Script technology is intended to deliver immediate- and extended-release opioid medications in a tamper-resistant form. If a medication formulated with SMART/Script were crushed or chewed, the SMART/Script...

Minister Aglukkaq announces new rules to address prescription drug abuse

2012-11-19 12:26:54

Calls on provinces, territories and medical professionals to also take action OTTAWA, Nov. 19, 2012 /CNW/ - To launch National Addictions Awareness Week, today the Honourable Leona Aglukkaq, Minister of Health, and Shelly Glover, Parliamentary Secretary to the Minister of Finance, announced tough new licencing rules that aim to clamp down on the diversion of controlled release formulations of oxycodone products - prescription drugs that are at a high risk of abuse. In a...

BioDelivery Sciences to Present at the 24th Annual Piper Jaffray Healthcare Conference

2012-11-19 08:27:40

RALEIGH, N.C., Nov. 19, 2012 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at the 24(th) Annual Piper Jaffray Healthcare Conference. The presentation is scheduled for Tuesday, November 27, 2012 at 11:50 a.m. Eastern Time, at The New York Palace in New York City. (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO ) Dr. Sirgo will focus on the clinical...